Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22.92 USD | -5.56% | -9.41% | -24.83% |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Mar. 22 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Evolution of the average Target Price on Intellia Therapeutics, Inc.
Price target over the last 5 years
History of analyst recommendation changes
Analysts' Consensus
Consensus detail
Consensus revision (last 18 months)
Analysts covering Intellia Therapeutics, Inc.
Canaccord Genuity | |
Wolfe Research | |
Morgan Stanley | |
Oppenheimer | |
Goldman Sachs | |
RBC Capital Markets | |
Wedbush | |
Barclays | |
Chardan Research | |
Citigroup | |
BMO Capital | |
Raymond James | |
JPMorgan Chase | |
Bernstein | |
Baird | |
Credit Suisse | |
EF Hutton | |
Cantor Fitzgerald | |
SVB Securities LLC | |
JMP Securities | |
Wells Fargo Securities | |
Piper Sandler | |
BofA Securities | |
Guggenheim | |
Brookline Capital Markets | |
William Blair & Co. | |
Cowen | |
HC Wainwright | |
Stifel Nicolaus | |
Chardan | |
Truist Securities | |
Roth Capital Partners | |
Jefferies & Co. |
EPS Revisions
- Stock Market
- Equities
- NTLA Stock
- Consensus Intellia Therapeutics, Inc.